Lawsuit Accuses GRAIL of Securities Fraud Over Cancer Test Data
A class action lawsuit has been filed against GRAIL, alleging investors were misled about the company's cancer test trial results. The company's stock price dropped significantly following the disclosure.
GRAIL, Inc. is facing a securities fraud class action lawsuit filed on behalf of investors who allege the company and its executives misled them regarding its NHS-Galleri cancer trial. The complaint claims GRAIL provided false and misleading statements about the trial's design and initial results, particularly concerning its ability to meet its primary endpoint within the specified timeframe.
The lawsuit stems from GRAIL's February 2026 announcement of top-line results from the NHS-Galleri trial. While the company highlighted certain positive findings, it also disclosed that the trial did not meet its primary endpoint of achieving a statistically significant reduction in Stage III-IV cancers. GRAIL noted that a longer follow-up period would likely have been necessary for adequate comparison.
Following this announcement, GRAIL's stock price fell by approximately 50.55%, dropping from $101.53 per share on February 19, 2026, to $50.21 per share on February 20, 2026. The case, Robbins v. GRAIL, Inc., is pending in the U.S. District Court for the Northern District of California, with a lead plaintiff deadline of August 4, 2026.
GRAIL, a commercial-stage company focused on early cancer detection with its Galleri test, is now defending against allegations related to its disclosure obligations and federal securities laws. The class action seeks to recover damages for investors who sustained losses due to the stock's sharp decline.